Close Menu

NEW YORK – Agilent Technologies reported after the close of the market on Monday that its fiscal fourth quarter revenues rose 6 percent year over year, thanks largely to an 8 percent increase in revenues for its crosslab unit and a 5 percent increase in revenues in its diagnostics and genomics business.

For the three months ended Oct. 31, the firm said revenues rose to $1.37 billion from $1.29 billion in Q4 2018, beating the average Wall Street estimate of $1.33 billion. The company said core revenues grew 4 percent year over year in Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.